KLRS
NASDAQKalaris Therapeutics Inc.
News25/Ratings7
News · 26 weeks36-20%
2025-10-262026-04-19
Mix2290d
- SEC Filings12(55%)
- Insider5(23%)
- Other4(18%)
- Analyst1(5%)
Latest news
25 items- ANALYSTMorgan Stanley initiated coverage on Kalaris Therapeutics with a new price targetMorgan Stanley initiated coverage of Kalaris Therapeutics with a rating of Overweight and set a new price target of $14.00
- SECSEC Form EFFECT filed by Kalaris Therapeutics Inc.EFFECT - Kalaris Therapeutics, Inc. (0001754068) (Filer)
- SECSEC Form EFFECT filed by Kalaris Therapeutics Inc.EFFECT - Kalaris Therapeutics, Inc. (0001754068) (Filer)
- SECSEC Form 424B3 filed by Kalaris Therapeutics Inc.424B3 - Kalaris Therapeutics, Inc. (0001754068) (Filer)
- SECSEC Form 424B3 filed by Kalaris Therapeutics Inc.424B3 - Kalaris Therapeutics, Inc. (0001754068) (Filer)
- SECSEC Form 8-K filed by Kalaris Therapeutics Inc.8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)
- SECSEC Form S-3 filed by Kalaris Therapeutics Inc.S-3 - Kalaris Therapeutics, Inc. (0001754068) (Filer)
- SECSEC Form S-3 filed by Kalaris Therapeutics Inc.S-3 - Kalaris Therapeutics, Inc. (0001754068) (Filer)
- INSIDERSEC Form 4 filed by Hagen Brett R4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- SECSEC Form 144 filed by Kalaris Therapeutics Inc.144 - Kalaris Therapeutics, Inc. (0001754068) (Subject)
- INSIDERSEC Form 4 filed by Oxtoby Andrew4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- INSIDERSEC Form 4 filed by Gall Matthew4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- INSIDERSEC Form 4 filed by Feinsod Matthew4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- SECSEC Form S-8 filed by Kalaris Therapeutics Inc.S-8 - Kalaris Therapeutics, Inc. (0001754068) (Filer)
- SECSEC Form 10-K filed by Kalaris Therapeutics Inc.10-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)
- SECSEC Form 8-K filed by Kalaris Therapeutics Inc.8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)
- PRKalaris Reports Full Year 2025 Financial Results and Provides Business UpdatesPositive initial data reported from Phase 1a Single Ascending Dose study in nAMD in December 2025; preliminary data from ongoing Phase 1b/2 study expected in 1H 2027 Intend to initiate Phase 3 clinical trials by year-end 2027 Completed oversubscribed $50.0 million private placement in December 2025 $118.0 million in cash, cash equivalents and marketable securities as of December 31, 2025 is expected to fund operations into the fourth quarter of 2027 and through key clinical milestones BERKELEY HEIGHTS, N.J., March 17, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical stage biopharmaceutical company dedicated to the development and commercializat
- SECSEC Form 8-K filed by Kalaris Therapeutics Inc.8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)
- INSIDERDirector Akkaraju Srinivas bought $5,000,006 worth of shares (479,847 units at $10.42) (SEC Form 4)4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Kalaris Therapeutics Inc.SCHEDULE 13D/A - Kalaris Therapeutics, Inc. (0001754068) (Subject)
- SECSEC Form SCHEDULE 13G filed by Kalaris Therapeutics Inc.SCHEDULE 13G - Kalaris Therapeutics, Inc. (0001754068) (Subject)
- PRKalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual MeetingBERKELEY HEIGHTS, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company developing differentiated therapies for retinal diseases, today announced that clinical data from its Phase 1 study of TH103 will be presented at the 49th Annual Meeting of the Macula Society, taking place February 25-28 in San Diego, California. TH103 is a novel investigational therapy engineered by VEGF scientific pioneer Dr. Napoleone Ferrara to achieve enhanced VEGF inhibition and increased intraocular retention. The presentation will include safety, tolerability, pharmacokinetics and early efficacy outcomes following intravitreal a
- ANALYSTChardan Capital Markets initiated coverage on Kalaris Therapeutics with a new price targetChardan Capital Markets initiated coverage of Kalaris Therapeutics with a rating of Buy and set a new price target of $19.00
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Kalaris Therapeutics Inc.SCHEDULE 13D/A - Kalaris Therapeutics, Inc. (0001754068) (Subject)
- INSIDERDirector Akkaraju Srinivas was granted 1,500,000 shares (SEC Form 4)4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)